Abstract
Morphea is a localized autoimmune fibrosing disorder that may paradoxically develop during anti-TNFα agents in ankylosing spondylitis (AS). We report a second case of morphea associated with long-term golimumab use in a patient with AS, presenting with indurated plaques and confirmed histopathologically. This case highlights the importance of clinical vigilance and timely dermatologic assessment to determine whether morphea represents a drug-induced reaction or an extra-articular manifestation of AS.